The agreement with CD8 Technology is likely to enhance Tevogen Bio's R&D and manufacturing capabilities, which is crucial for a clinical-stage biotech company. The $36 million line of credit provides financial stability, supporting continued operations and potential growth. This news is likely to positively impact TVGN's stock price in the short term.